Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-29
2006-08-29
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S332000, C546S329000
Reexamination Certificate
active
07098226
ABSTRACT:
A purpose of the present invention is to provide TNF-α production inhibitors being useful as therapeutic agents for autoimmune diseases such as rheumatoid arthritis. Novel compounds having the structure represented by the general formula [1] or salts thereof according to the present invention have excellent TNF-α production inhibitory activities,wherein “A” is —(NR4)—, —(CR5R6)— or —O—, “B” is alkylene or alkenylene, R1, R2, R4, R5and R6are hydrogen, alkyl, alkenyl, adamantyl or the like, R3is aryl or an unsaturated heterocycle, and “X” is oxygen or sulfer respectively.
REFERENCES:
patent: 3682922 (1972-08-01), Klimstra
patent: 4597902 (1986-07-01), Shanklin, Jr. et al.
patent: 4724235 (1988-02-01), Shanklin, Jr. et al.
patent: 5173506 (1992-12-01), Neustadt et al.
patent: 5190974 (1993-03-01), Clemence et al.
patent: 5356925 (1994-10-01), Neustadt et al.
patent: 5599944 (1997-02-01), M uller et al.
patent: 5674864 (1997-10-01), Clemence et al.
patent: 6033443 (2000-03-01), Aeschlimann
patent: 6034096 (2000-03-01), Bertolini et al.
patent: 6420398 (2002-07-01), Mita et al.
patent: 6492370 (2002-12-01), Mita et al.
patent: 2001/0041725 (2001-11-01), Mita et al.
patent: 2002/0077357 (2002-06-01), Mita et al.
patent: 2002/0198376 (2002-12-01), Mita et al.
patent: 2005/0014800 (2005-01-01), Matsuoka et al.
patent: 0 849 256 (1998-06-01), None
patent: 0 903 434 (1999-03-01), None
patent: 1072591 (2001-01-01), None
patent: 1103543 (2001-05-01), None
patent: 1 457 205 (2004-09-01), None
patent: 9-508115 (1997-08-01), None
patent: WO 92/03410 (1992-03-01), None
patent: WO 92/07567 (1992-05-01), None
patent: WO 95/19957 (1995-07-01), None
patent: WO 97/24328 (1997-07-01), None
patent: WO 97/24355 (1997-07-01), None
patent: WO 97/43251 (1997-11-01), None
patent: WO 98/27069 (1998-06-01), None
patent: WO 99/50238 (1999-10-01), None
patent: WO 00/07985 (2000-02-01), None
patent: WO 00/61552 (2000-10-01), None
Buschauer, A.: Synthesis and in Vitro pharmacology of Arpromidine and related phenyl(pyridylalkyl)guanidines, a potential new class of positive inotropic drugs. J. Med. Chem. vol. 32, pp. 1963-1970, 1989.
Starnes, S.D.; Rudkevich, D.M.; Rebek, J. Jr., “A Cavitand-Porphyrin Hybrid”, Org. Lett., 2000, vol. 2, No. 14, pp. 1995-1998.
Yamazaki, Clinical Immunology, 27, pp. 1270-1273 (1995) and English language Abstract thereof.
Andreas Eigler et al, Immunology Today, 18, pp. 487-492, (1997).
Kurose et al., “Asymmetric [2,3] Sigmatropic Rearrangement of Chiral Allyic Selenimides”,J. Org. Chem., (1996), vol. 61, pp. 2932-2933, XP001157480.
Braña et al., “Synthesis of 1,2-Di-(4-pyridyl)ethylenediamine and Related Compounds”,J. Heterocycl. Chem., (1987), vol. 24, pp. 369-371, XP009010907.
Mayer et al., “183. Structural Factors Affecting the Basicity of ω-Pyridylalkanols, ω-Pyridylalkanamides and ω-Pyridylalkylamines”,Helvetica Chimica Acta, (1982), vol. 65, Fasc. 6, No. 183, pp. 1868-1884, XP009010908.
A.R. Katritzky, “An Attempt to Simulate the Biogenesis of Stychnine. Part II. Preparation and Transformations of 3-(2-4′-Pyridylacetamidoethyl)indole.”, (1955), pp. 2586-2593, XP009010909.
Böhme et al., “α-Alkylmercapto- and α-Aryolmercapto-alkylisocyanate”,Archiv Pharm. Ber. Dtsch. Pharm. Ges., (1969), vol. 302, No. 5, pp. 335-339, XP009010911.
Shoeb et al., “Studies in Possible Oral Hypoglycaemic Agents: Part V-Synthesis of Carbamoylindoles, Carbamoylisoindolines, 3-Indolylethyl Urea (or Thiourea) & 2- Isoindolinylpropyl Urea (or Thiourea) Derivatives & Their Biological Activity”,J. Chem., (1967), vol. 5, pp. 142-144, XP009010912.
Kunz et al., “Der. 2-(4-Pyridyl)Ethoxycarbonyl-(4-Pyoc)-Rest-Eine Hydrophile . . . ”,Tetrahedron Letters, (1984), vol. 25, No. 33, pp. 3567-3570, XP009010914.
Ban Masakazu
Enomoto Hiroshi
Horiuchi Masato
Inoue Hiroyuki
Suhara Hiroshi
Aulakh Charanjit S.
Frishauf Holtz Goodman & Chick P.C.
Santen Pharmaceutical Co. Ltd.
LandOfFree
TNF-α production inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TNF-α production inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TNF-α production inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3608089